The Evolution of Screening Tools for Prostate Cancer
The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content: A Pragmatic Approach to Prostate Cancer Screening Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - April 6, 2024 Category: General Medicine Authors: JAMA Network Source Type: podcasts
Why we need to rethink how we talk about cancer
For over a century, cancer has been classified by areas of the body - lung cancer, breast cancer, skin cancer etc. And yet modern medical research is telling us that the molecular and genetic mechanisms behind cancers are not necessarily tied to parts of the body. Many drugs developed to treat metastatic cancers have the capacity to work across many different cancers, and that presents an opportunity for more tailored and efficient treatments. Oncologists are calling for a change in the way patients, clinicians and regulators think about naming cancers.In this podcast, senior comment editor Lucy Odling-...
Source: Nature Podcast - February 9, 2024 Category: Science Authors: Springer Nature Limited Source Type: podcasts
Mood Symptoms After Dobbs, Prostate Cancer Treatment Outcomes, Speech and Language Delay Screening in Children, and more
Editor’s Summary by Kristin Walter, MD, MS, Deputy Editor of JAMA, the Journal of the American Medical Association, for the January 23/30, 2024, issue. Related Content: Audio Highlights (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - January 23, 2024 Category: General Medicine Authors: JAMA Network Source Type: podcasts
JAMA Oncology : Shorter-Course Radiotherapy for Prostate Cancer
Interview with Daniel E. Spratt, MD, author of Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. Hosted by Jack West, MD. Related Content: Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 5, 2023 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
JAMA Oncology : Prostate-Specific Antigen Screening Rates and Metastatic Prostate Cancer Incidence in the VHA
Interview with Brent S. Rose, MD, author of Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities. Hosted by Jack West, MD. Related Content: Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 24, 2022 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
JAMA Oncology : Association of 5 α-Reductase Inhibitors With Prostate Cancer Mortality
Interview with Lars Björnebo, MSc, and Anna Lantz, MD, PhD, authors of Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. Hosted by Jack West, MD. (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - May 19, 2022 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
In conversation with... Nick James
Nick James discusses the key messages of the recent report from the STAMPEDE trial platform and the success of this platform in advancing the treatment of prostate cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - December 23, 2021 Category: General Medicine Authors: The Lancet Source Type: podcasts
Online Weight Management for Weight Loss, Prostate Cancer Outcomes for AA Men, Venous Thromboembolism Review, and more
Editor's Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the November 3, 2020 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - November 3, 2020 Category: General Medicine Authors: JAMA Network Source Type: podcasts
JAMA Oncology : Tailoring Intensity of Surveillance for Prostate Cancer Based on Prediction of Risk Stability
Interview with Matthew R. Cooperberg, MD MPH, author of Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - August 27, 2020 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
JAMA Oncology : HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Interview with Nima Sharifi, M.D., author of HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - February 13, 2020 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
JAMA Oncology : Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute –Designated Cancer Centers
Interview with Trevor J. Royce, MD MS MPH, author of Analysis of Price Transparency via National Cancer Institute–Designated Cancer Centers’ Chargemasters for Prostate Cancer Radiation Therapy (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - January 16, 2020 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic hormone-sensitive prostate cancer.
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-365 in mCRPC Results
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer ...
Author: obr
Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts
